Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof H G
Department of Neurosurgery, University Hospital Zurich, Switzerland.
Clin Neurol Neurosurg. 1997 Oct;99 Suppl 2:S58-60. doi: 10.1016/s0303-8467(97)00042-5.
A questionnaire was distributed in early 1996 to 160 leading European neurological, neuro-pediatric and neurosurgical centers to assess the present status of Moyamoya disease in Europe. The response rate was 43%. Information was obtained on a total of 168 patients, of whom 110 had presented before 1992, and 58 from 1993 onward. 82% of the patients were Caucasian. In all other respects, the clinical findings were similar to those observed in Japan. The present study yields an incidence of 0.3 patients per center per year, which is approximately one-tenth of the incidence in Japan. Alongside these results, the history of the recognition and treatment of this disease in Europe is briefly discussed.
1996年初,一份调查问卷被分发给160家欧洲顶尖的神经科、神经儿科和神经外科中心,以评估欧洲烟雾病的现状。回复率为43%。共获得了168例患者的信息,其中110例于1992年前就诊,58例于1993年及以后就诊。82%的患者为白种人。在所有其他方面,临床发现与在日本观察到的相似。本研究得出的发病率为每个中心每年0.3例患者,约为日本发病率的十分之一。除了这些结果,还简要讨论了欧洲对这种疾病的认识和治疗历史。